In the United States, a viral liver infection that has long forced patients to endure without any approved medicine has finally met a drug of its own. The Food and Drug Administration has cleared Hepcludex, an injectable from Gilead Sciences known generically as bulevirtide, for adults living with chronic hepatitis delta, whether their livers are unscarred or scarred yet still working. The decision rests on a trial in which half the participants received the drug at once and half waited, and it arrives as a hard-won step in a long search for relief, with the promise tempered by the reminder th
FDA Approves Gilead's Hepcludex, the First FDA-Approved Therapy for Chronic Hepatitis Delta
Chronic hepatitis delta can rapidly progress to serious liver complications, and patients have had no FDA-approved treatment options until now.
A first treatment for a disease that had none approved
Mark
Why is this approval a big deal if the drug has existed elsewhere?
Mimi
Because in the U.S. there was nothing approved at all. The FDA's own statement says patients had no approved therapies until now.
Luke
Worth noting the source doesn't discuss other countries, so I'd stay with what's confirmed: first approved therapy here.
Mark
What did the trial actually show?
Mimi
At week 48, 20 percent on Hepcludex had undetectable HDV RNA, versus 0 percent in the delayed group. That rose to 36 percent at week 96 and 50 percent at week 144.
Luke
And that means half the treated group, by week 144, had undetectable virus. It doesn't say what happened to the other half, and the report gives no liver outcome data.
Mark
Why accelerated approval?
Mimi
The source states the pathway but doesn't explain the reasoning. It does say priority review, Breakthrough and Orphan designations also applied.
Luke
Right, so I wouldn't read more into the pathway than that. Accelerated approval generally signals further confirmation is expected, but the article doesn't spell out any requirements.
Mark
And the boxed warning?
Mimi
Stopping may cause severe acute exacerbations of HDV and hepatitis B. For a daily drug, that's central to the decision.
Luke
Agreed. What we don't know from this reporting is cost, availability, or how many patients are eligible.
The Pulse
- For years, Americans with hepatitis delta have faced a severe liver infection with no approved medicine to turn to.
- The approval arrives on an accelerated track, meaning the evidence rests on virus suppression rather than final proof of long-term outcomes.
- A boxed warning now sits on the label: halting treatment can trigger severe flares of both delta and hepatitis B.
- Half of the patients who stayed on the drug for 144 weeks reached undetectable virus, giving clinicians a first real tool and a long road of monitoring ahead.
In the United States, a viral liver infection that has long forced patients to endure without any approved medicine has finally met a drug of its own. The Food and Drug Administration has cleared Hepcludex, an injectable from Gilead Sciences known generically as bulevirtide, for adults living with chronic hepatitis delta, whether their livers are unscarred or scarred yet still working. The decision rests on a trial in which half the participants received the drug at once and half waited, and it arrives as a hard-won step in a long search for relief, with the promise tempered by the reminder that stopping the medicine may bring dangerous flares.
For people in the United States living with chronic hepatitis delta, a viral liver infection that can move quickly toward serious liver damage, the medical options have until now been limited to managing symptoms and watching closely. That changed when the Food and Drug Administration approved Hepcludex, made by Gilead Sciences and known generically as bulevirtide, for adults whose livers are either unscarred or have compensated cirrhosis, meaning scarring that the organ still compensates for.
The agency acted under its Accelerated Approval pathway, following a priority review, and the drug also carried Breakthrough Therapy and Orphan Drug designations. The evidence came from a Phase III trial in which participants were assigned at random. Some began daily injections right away, while others waited 48 weeks before starting treatment.
The key measure was whether the virus fell below the limit of detection. At week 48, 20 percent of the immediate group had reached that point, while none of the delayed group had. Among those who continued treatment, the figure climbed to 36 percent by week 96 and 50 percent by week 144.
The boxed warning, the FDA's most serious label notice, cautions that stopping Hepcludex can provoke severe flares of both delta and hepatitis B. For a medicine meant to be taken daily for years, that caution will shape how patients and doctors weigh every decision about continuing or pausing care.
FDA officials described the approval as filling a critical gap for patients who had no approved therapy. What remains to be seen is how the drug performs over the long haul and how the warning guides real choices about treatment.
The U.S. Food and Drug Administration has approved the first treatment in the United States for chronic hepatitis delta, a viral liver infection that, until now, patients here have had to manage without any approved drug. The product is Hepcludex, known generically as bulevirtide-gmod, an injection made by Gilead Sciences.
The approval covers adults with chronic hepatitis delta virus infection, abbreviated HDV, who either have no cirrhosis or have compensated cirrhosis, meaning the liver is scarred but still functioning. The agency granted it under its Accelerated Approval pathway after a priority review. Hepcludex also carried two other designations along the way: Breakthrough Therapy and Orphan Drug, the latter reserved for treatments aimed at rare conditions.
The decision rests on a Phase III trial that split participants into two groups at random. One group began treatment with Hepcludex immediately, taking 8.5 mg once daily for 144 weeks. The other waited through a 48-week observational period and then started treatment.
The measure that mattered was undetectable HDV RNA, defined as a level below 50 IU/mL, the lower limit of quantification. At week 48, 20 percent of those in the immediate-treatment group had reached that mark, compared with none of the delayed-treatment group. Among those who stayed on Hepcludex, the share with undetectable virus rose to 36 percent at week 96 and 50 percent at week 144.
The label carries a boxed warning, the FDA's most prominent kind. Stopping Hepcludex may cause severe acute flare-ups of both HDV and hepatitis B virus infection. That detail matters for a drug taken daily over a period measured in years.
Wendy Carter, D.O., of the FDA's Center for Drug Evaluation and Research, framed the decision in terms of the gap it closes. In a statement she said the approval fills a critical hole in care for patients with chronic HDV, who until now had no FDA-approved therapy. She added that the treatment offers hope for managing a disease that can progress rapidly to serious liver complications.
Because the approval came through the accelerated route, it reflects results on a virologic measure, undetectable virus, rather than a final verdict on long-term outcomes. What to watch next is how the drug performs for patients who take it over the full course, and how the boxed warning shapes decisions about when, and whether, anyone can safely stop.
Notable Quotes
Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available.— Wendy Carter, D.O., FDA Center for Drug Evaluation and Research
Want the full story?
Read the original at Medical Xpress ↗
Health & Medicine